GLP-1 receptor agonists

Descripción del Articulo

The evolution and discovery of a molecule derived from the proglucagon with incretinic effect is described. In the search for a molecule resistant to the rapid metabolism caused by DPP-4, it was found molecules such as Exendin 4 and subsequently the synthetic ones, specific to the GLP-1 receptor and...

Descripción completa

Detalles Bibliográficos
Autor: Arbañil- Huamán, Hugo César
Formato: artículo
Fecha de Publicación:2020
Institución:Fundación Instituto Hipólito Unanue
Repositorio:Diagnóstico
Lenguaje:español
OAI Identifier:oai:revistadiagnostico.fihu.org.pe:article/219
Enlace del recurso:https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/219
Nivel de acceso:acceso abierto
Materia:Diabetes Mellitus tipo 2
tratamiento
agonistas receptor GLP-1
Diabetes Mellitus type 2
treatment
GLP-1 receptor agonists
id REVFIHU_8f43a32e15966fd0120fcb0ef0dc1250
oai_identifier_str oai:revistadiagnostico.fihu.org.pe:article/219
network_acronym_str REVFIHU
network_name_str Diagnóstico
repository_id_str
spelling GLP-1 receptor agonistsAgonistas del receptor de GLP-1Arbañil- Huamán, Hugo CésarDiabetes Mellitus tipo 2tratamientoagonistas receptor GLP-1Diabetes Mellitus type 2treatmentGLP-1 receptor agonistsThe evolution and discovery of a molecule derived from the proglucagon with incretinic effect is described. In the search for a molecule resistant to the rapid metabolism caused by DPP-4, it was found molecules such as Exendin 4 and subsequently the synthetic ones, specific to the GLP-1 receptor and resistant to the metabolism of DPP-4. It was also found that they had cardiovascular and renal advantages in the safety studies before their were approved, in particular the longacting and parenteral ones but not those of oral absorption.Se describe la evolución y descubrimiento de una molécula derivada del proglucagón con efecto incretínico, en la búsqueda de una molécula resistente al rápido metabolismo ocasionado por la DPP-4, se encontró y desarrolló moléculas como el Exendin 4 y posteriormente las moléculas sintéticas, específicas para el receptor de GLP-1 y resistentes al metabolismo de DPP-4 y con efecto beneficioso cardiovascular y renal en los estudios de seguridad antes de su aprobación, en particular los de larga acción y parenterales, no así los de absorción oral.Fundación Instituto Hipólito Unanue2020-11-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/21910.33734/diagnostico.v59i2.219Diagnóstico; Vol. 59 No. 2 (2020); 65-68Diagnostico; Vol. 59 Núm. 2 (2020); 65-681018-28882709-795110.33734/diagnostico.v59i2reponame:Diagnósticoinstname:Fundación Instituto Hipólito Unanueinstacron:FIHUspahttps://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/219/223Derechos de autor 2020 Hugo César Arbañil- Huamáninfo:eu-repo/semantics/openAccessoai:revistadiagnostico.fihu.org.pe:article/2192021-06-04T17:58:41Z
dc.title.none.fl_str_mv GLP-1 receptor agonists
Agonistas del receptor de GLP-1
title GLP-1 receptor agonists
spellingShingle GLP-1 receptor agonists
Arbañil- Huamán, Hugo César
Diabetes Mellitus tipo 2
tratamiento
agonistas receptor GLP-1
Diabetes Mellitus type 2
treatment
GLP-1 receptor agonists
title_short GLP-1 receptor agonists
title_full GLP-1 receptor agonists
title_fullStr GLP-1 receptor agonists
title_full_unstemmed GLP-1 receptor agonists
title_sort GLP-1 receptor agonists
dc.creator.none.fl_str_mv Arbañil- Huamán, Hugo César
author Arbañil- Huamán, Hugo César
author_facet Arbañil- Huamán, Hugo César
author_role author
dc.subject.none.fl_str_mv Diabetes Mellitus tipo 2
tratamiento
agonistas receptor GLP-1
Diabetes Mellitus type 2
treatment
GLP-1 receptor agonists
topic Diabetes Mellitus tipo 2
tratamiento
agonistas receptor GLP-1
Diabetes Mellitus type 2
treatment
GLP-1 receptor agonists
description The evolution and discovery of a molecule derived from the proglucagon with incretinic effect is described. In the search for a molecule resistant to the rapid metabolism caused by DPP-4, it was found molecules such as Exendin 4 and subsequently the synthetic ones, specific to the GLP-1 receptor and resistant to the metabolism of DPP-4. It was also found that they had cardiovascular and renal advantages in the safety studies before their were approved, in particular the longacting and parenteral ones but not those of oral absorption.
publishDate 2020
dc.date.none.fl_str_mv 2020-11-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/219
10.33734/diagnostico.v59i2.219
url https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/219
identifier_str_mv 10.33734/diagnostico.v59i2.219
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://revistadiagnostico.fihu.org.pe/index.php/diagnostico/article/view/219/223
dc.rights.none.fl_str_mv Derechos de autor 2020 Hugo César Arbañil- Huamán
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2020 Hugo César Arbañil- Huamán
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
publisher.none.fl_str_mv Fundación Instituto Hipólito Unanue
dc.source.none.fl_str_mv Diagnóstico; Vol. 59 No. 2 (2020); 65-68
Diagnostico; Vol. 59 Núm. 2 (2020); 65-68
1018-2888
2709-7951
10.33734/diagnostico.v59i2
reponame:Diagnóstico
instname:Fundación Instituto Hipólito Unanue
instacron:FIHU
instname_str Fundación Instituto Hipólito Unanue
instacron_str FIHU
institution FIHU
reponame_str Diagnóstico
collection Diagnóstico
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1847792815894953984
score 13.0585375
GLP-1 receptor agonists
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).

Ejemplares Similares